enGene Reports Second Quarter 2026 Financial Results and Provides Business Update (opens original article in a new tab)

enGene Therapeutics reported Q2 2026 financial results, including a net loss of $30.2 million, and provided updates on clinical trials for its drug detalimogene, which showed a 54% complete response rate in high-risk NMIBC patients. The company also announced a 50% workforce reduction to conserve cash and plans to meet with the FDA in the second half of 2026 regarding a BLA submission.

• enGene reports Q2 2026 financial results with a net loss of $30.2 million.
• Clinical data from LEGEND Cohort 1 shows 54% complete response rate for detalimogene without surfactant in high-risk NMIBC patients.
• Company downsizes workforce by 50% to conserve cash and plans to engage with FDA in 2H 2026 for BLA submission.